2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

By L. Hanuš, S. Abu-Lafi, E. Fride, A. Breuer, Z. Vogel, D. E. Shalev, I. Kustanovich, R. Mechoulam. Proceedings of the National Academy of Sciences of the United States of America, 2001

788 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology, Toxicology

View Paper: https://www.semanticscholar.org/paper/d83d28323406ba16638e539adc6426e69003cd8e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. R. Pertwee
2. V. Di Marzo
3. K. Mackie
4. R. Ross
5. George Kunos
6. T. Klein
7. R. Mechoulam
8. Allyn C. Howlett

In Pharmacology

1. R. Pertwee
2. V. Di Marzo
3. K. Mackie
4. George Kunos
5. T. Klein
6. R. Ross
7. R. Mechoulam
8. Allyn C. Howlett

In Toxicology

1. George Kunos
2. V. Di Marzo

Citations in the corpus

• Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration (2003, background): “, noladin) that is an analog of 2-AG that acts on CB1 receptors (Hanus et al., 2001).”
• Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. (2002, background): “Very recently, a third endocannabinoid, noladin ether, was also isolated from porcine brain (Hanus et al., 2001).”
• Pharmacological actions of cannabinoids. (2005, background): “Another CB1-selective agonist of note is the endocannabinoid 2-arachidonyl glyceryl ether (Hanus et al. 2001), the”
• International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (2010, background): “Noladin ether (2-arachidonyl glyceryl ether) (Hanus et al., 2001) is also a CB1-selective agonist.”
• Cannabinoid-based drugs as anti-inflammatory therapeutics (2005, background): “1h ) and 2-arachidonylglyceryl ether (also known as noladin ether”
• Stress-induced analgesia. (2009, neutral): “46 among others (Devane et al., 1992; Hanus et al., 2001; Huang et al., 2002; Mechoulam et al., 1995; Porter et al., 2002; Sugiura et al., 1995).”
• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors (2002, background): “These have generated data indicating that in contrast to anandamide and 2-arachidonoylglycerol, noladin ether has much higher affinity for CB 1 receptors than for CB 2 receptors (Hanus et al., 2001; Table 2).”
• Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. (2006, background): “…receptors (Cnrs) (Chakrabarti et al., 1995; Matsuda et al., 1990; Munro et al., 1993), isolation of endocannabinoids (eCBs) (Devane et al., 1992; Hanus et al., 2001; Mechoulam and Parker, 2003; Onaivi et al., in press; Porter et al., 2002; Sugiura et al., 1995; Tsou et al., 1998) and entourage…”
• CB2: a cannabinoid receptor with an identity crisis (2010, background): “Around the time that CB1 and CB2 were cloned, anandamide and 2-arachidonylglycerol (2-AG) were identified as endogenous cannabinoid agonists (Devane et al., 1992; Felder et al., 1993; Sugiura et al., 1995; Hanus et al., 2001).”
• The emerging role of the endocannabinoid system in endocrine regulation and energy balance. (2006, neutral): “Specifically, these compounds are 2-arachidonoyl-glyceryl-ether (noladin ether) (92), O-arachidonoyl-ethanolamine (virodhamine) (93), N-arachidonoyl-dopamine (94), and possibly oleamide (95).”
• Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol (2002, background): “…2001a), with both the exogenous cannabinoid, D9-tetrahydrocannabinol (D9 -THC) and anandamide reported to reliably induce overeating (Foltin et al., 1988; Williams & Kirkham, 1998; Williams & Kirkham, 1999; 2002a; Hao et al., 2000; Jamshidi & Taylor, 2001; Koch, 2001; Koch & Matthews, 2001).”